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Abstract
Immunity to a sand fly salivary protein protects against visceral leishmaniasis (VL) in hamsters. This protection was
associated with the development of cellular immunity in the form of a delayed-type hypersensitivity response and the
presence of IFN-c at the site of sand fly bites. To date, there are no data available regarding the cellular immune response to
sand fly saliva in dogs, the main reservoirs of VL in Latin America, and its role in protection from this fatal disease. Two of 35
salivary proteins from the vector sand fly Lutzomyia longipalpis, identified using a novel approach termed reverse antigen
screening, elicited strong cellular immunity in dogs. Immunization with either molecule induced high IgG2 antibody levels
and significant IFN-c production following in vitro stimulation of PBMC with salivary gland homogenate (SGH). Upon
challenge with uninfected or infected flies, immunized dogs developed a cellular response at the bite site characterized by
lymphocytic infiltration and IFN-c and IL-12 expression. Additionally, SGH-stimulated lymphocytes from immunized dogs
efficiently killed Leishmania infantum chagasi within autologous macrophages. Certain sand fly salivary proteins are potent
immunogens obligatorily co-deposited with Leishmania parasites during transmission. Their inclusion in an anti-Leishmania
vaccine would exploit anti-saliva immunity following an infective sand fly bite and set the stage for a protective anti-
Leishmania immune response.
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Introduction
Leishmaniasis is a vector-borne neglected disease transmitted
exclusively by the bite of infected phlebotomine sand flies. An
estimated 350 million people are at risk for leishmaniasis with an
annual incidence of 2 million cases and a loss of 2,357,000
disability-adjusted life years [1,2,3]. Leishmaniasis presents with
multiple clinical manifestations including cutaneous, mucocutane-
ous, diffuse and visceral (VL) infections. The latter is responsible
for 59,000 deaths a year, a parasitic disease statistic surpassed only
by malaria [4]. There are two types of VL, anthroponotic and
zoonotic. Zoonotic VL (ZVL) is wide spread and occurs in Latin
America, Northern Africa, Southern Europe and areas of the
Middle East and Asia [5,6,7]. The dog is considered the main
reservoir of ZVL [5,8]. Indeed, there is a clear association between
a high rate of infection in dogs and an increased risk of human
disease [3]. An anti-Leishmania canine vaccine would not only
protect dogs from a fatal disease but could have a considerable
effect on reducing human infections.
Understandably, the search for vaccine candidates for leish-
maniasis has focused on Leishmania antigens [9]. Several promising
first, second and third generation vaccine candidates produced
variable levels of protection in animal models [9]. Still there are no
available human vaccines for any form of leishmaniasis and
LEISHMUNE, a canine vaccine based on a Leishmania infantum
chagasi fucose-mannose-ligand glycoprotein fraction [10], is only
licensed in Brazil [11]. Although LEISHMUNE has demonstrated
some efficacy against canine visceral leishmaniasis (CVL) it has
limitations that include safety issues and the difficulty to
serologically distinguish asymptomatic from vaccinated dogs
[11,12].
Sand fly salivary proteins are inoculated at the site of parasite
deposition during transmission by infective sand fly bites. Thus,
immunogenic salivary proteins that influence the immune status
of the host can potentially have consequences on the outcome
of leishmaniasis. This hypothesis has been corroborated in
rodent models where immunization with sand fly saliva or a
distinct salivary protein conferred protection against both
cutaneous and visceral leishmaniases [13,14,15,16,17]. This
protection has been correlated with a Th1 response against
salivary antigens characterized by the presence of IFN-c at the
bite site [14,17].
PLoS Pathogens | www.plospathogens.org 1 May 2009 | Volume 5 | Issue 5 | e1000441The above puts forward a solid argument for the use of salivary
gland proteins of appropriate vector sand fly species to improve
the efficacy and immunogenicity of Leishmania-based vaccine
candidates. In this study, immunization of dogs with two novel
salivary proteins from Lutzomyia longipalpis, the only established
vector of L. i. chagasi in Latin America, resulted in a strong systemic
and local Th1 cell-mediated immunity that was efficiently recalled
by sand fly bites and adversely affected parasite survival in vitro. To
our knowledge, this is the first demonstration that specific
immunity to a salivary protein can be elicited in a natural host
of the Leishmania parasite and an endorsement for the use of
salivary proteins, neglected thus far, as novel antigens in anti-
Leishmania vaccines.
Results
Bites of Lutzomyia longipalpis sand flies induce a strong
delayed type hypersensitivity response in dogs
In rodent models, cellular immunity characterized by a Th1
delayed type hypersensitivity (DTH) response to sand fly salivary
proteins protected animals from cutaneous and visceral leishman-
iases [16,17]. Up to date, there is no information pertaining to the
presence and nature of cellular immunity to sand fly saliva in dogs,
the main reservoirs of ZVL [5]. Here, we explored the early
kinetics of anti-saliva immunity in dogs following exposure to bites
of Lu. longipalpis, the vector of L. i. chagasi in Latin America. Seven
of nine beagles showed specific anti-saliva antibodies one week
after the third exposure to sand fly bites (Figure 1A). Apart from a
single dog with a mixed IgG2/IgG1 antibody response, these
animals showed a strong IgG2 response and no IgG1 (Figure 1A).
To investigate whether dogs exposed to sand fly bites develop a
DTH response, we measured the skin induration at the bite site
following each sand fly exposure. Following the second exposure, a
small induration was observed in the 7 dogs that produced
significant levels of antibodies (Figure 1B). This was characterized
by a localized erythema, swelling and thickening of the skin. The
intensity and duration of the observed induration was significantly
increased following the third sand fly exposure lasting up to 96 h
following sand fly bites (Figure 1B). No reaction was observed in
naive animals after the first exposure. Histological analysis of the
induration site 48 h following the first and second exposure shows
minimal inflammation characterized by scattered perivascular
lymphocytes and rare neutrophils within the superficial dermis
(Figure 1C). A dramatic increase in the cellular infiltrate was noted
48 h following the third exposure, characterized by a prominent
thickening of the epidermis and multifocal infiltrates of lympho-
cytes, macrophages and eosinophils (Figure 1D). The timing of the
reaction as well as the nature of the infiltrate established that sand
fly saliva induces a DTH reaction in the skin of dogs after repeated
exposures.
Salivary proteins LJL143 and LJM17 produce a DTH
response in dogs
Immunization with a single DTH inducing salivary molecule
conferred protection from cutaneous and visceral leishmaniases in
rodent models [16,17]. To identify the salivary molecules
responsible for the generation of a DTH response in dogs, we
screened 35 DNA plasmids encoding secreted salivary proteins of
Lu. longipalpis [18] using a novel approach we termed reverse
antigen screening (RAS). Five dogs were exposed to sand fly bites
then injected individually with up to 38 samples including three
controls (Figure 2A). Out of the 35 salivary DNA plasmids only
four (LJL143, LJM17, LJM11 and LJL138) induced a macroscopic
DTH response 48 h after challenge defined by a strong erythema
with or without palpable induration in at least three of five dogs
(Figure 2B). This DTH response was highly specific as shown in
Figure 2C. Since induration is an important indicator of cellular
recruitment, we focused on LJL143 and LJM17 that produced the
strongest combined responses in at least 3 dogs (Figure 2B,D).
Histological analysis of injection sites 48 h post-challenge showed
that LJL143 and LJM17 induce a typical DTH response
characterized by considerable lymphocytic infiltration with few
macrophages (Figure 2E). This recruitment was comparable to
that of SGH (positive control) and was absent for LJM111
(negative control) as well as the vector control and PBS (data not
shown). Analysis of the DTH site for expression of selected
cytokines associated with Th1 or Th2 responses showed an
appreciable induction of IL-12, a moderate expression of IFN-c
and low expression of TGFb for LJM17 (Figure 2F). LJL143
showed a mixed response with IL-12 and IL-4 expression
(Figure 2F). In comparison, SGH showed considerable expression
levels of the four investigated cytokines (Figure 2F). There was
minimal to no expression of any of the cytokines tested in negative
controls (Figure 2F). To validate the specificity of the observed
antigenic properties of LJL143 and LJM17 plasmids, 300 ng of
purified recombinant proteins (Figure 3A) were injected in the five
dogs previously exposed to DNA plasmids and in two more dogs
pre-exposed to sand fly bites alone. In addition, 300 ng of
rLJM111, a non-reactive sand fly salivary molecule, 300 ng of
rTB179, a non-related tick salivary protein (negative controls) and
a pair of SGH (positive control) were simultaneously injected. A
clear DTH response was observed 48 h following the injection of
rLJL143 and rLJM17. The DTH response was characterized by
erythema with or without palpable induration (Figure 3B) and
cellular infiltration (Figure 3C) comparable to those observed
following the injection of DNA plasmids (Figure 2C,E). As
predicted, rLJM111, rTB179 and PBS showed no erythema or
induration (Figure 3B). The absence of cellular infiltration was
confirmed by histology for rLJM111 (Figure 3C). It is worth noting
that LJM111 remained non-reactive following the injection of the
Author Summary
Leishmaniasis is a neglected infectious disease with a
global distribution encompassing 88 countries, 350 million
people at risk, and an annual incidence of 2 million cases.
Leishmaniasis is a vector-borne disease transmitted by
sand fly bites where parasites are co-deposited with saliva
into the wound. Our group has demonstrated that distinct
molecules in the saliva of various sand fly species drive an
immune response that protects experimental rodent
models from self-healing cutaneous and fatal visceral
leishmaniasis. Here we show for the first time that dogs,
natural reservoirs of visceral leishmaniasis, develop a
strong immune response to two salivary proteins from
the natural vector sand fly. Blood from immunized dogs
contained immune cells that produced molecules (IFN-c)
typically associated with protection from Leishmania
parasites. This response efficiently recruited appropriate
immune cells to the site of sand fly bites in the skin and
had an adverse effect on Leishmania parasites in an
experimental assay. These findings suggest that inclusion
of these salivary molecules in anti-Leishmania canine
vaccines would enhance their efficiency in protecting
dogs from visceral leishmaniasis. A successful anti-Leish-
mania canine vaccine would not only protect dogs from a
fatal disease but could have a considerable effect on
reducing human infections.
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challenged with the DNA plasmid encoding that protein.
Strong induction of a Th1 humoral and cellular immunity
in dogs immunized with LJL143 and LJM17
It is well established that a Th1 cell-mediated immunity (CMI),
characterized by the production of IFN-c, is critical for protection
from Leishmania infection [19]. Using RAS, LJL143 and LJM17
were identified as vaccine candidates following the induction of a
DTH response in dogs previously exposed to Lu. longipalpis bites
(Figures 2 and 3). Subsequently, naı ¨ve dogs were immunized with
LJL143 and LJM17 using DNA plasmids followed by a
recombinant protein boost. Both LJL143 and LJM17 induced a
strong humoral response (Figure 4A) that was efficiently recalled
Figure 1. Dogs develop a strong humoral and cellular immune response to bites of Lu. longipalpis sand flies. Dogs (n=9) were exposed
for 10 min to bites of 20 sand flies three times at one week intervals (first exposure, E1; second exposure, E2; third exposure, E3). (A) Weekly
measurement of IgG, IgG1 and IgG2 antibody levels in dogs exposed to sand flies. (B) Induration score in a representative dog 48 h after each of three




2 and 4.10 cm
2. (C) Representative H&E staining of biopsies taken from sand fly bite sites prior to exposure (E0) and
48 h after each of three sand fly exposures (E1–E3). Note marked cellular infiltrate within dermis and thickening of epidermis in E3. (D)
Immunohistochemical labeling of tissue sections from E3 demonstrating the presence of abundant CD3+T cells (CD3), macrophages (Mac387) and
eosinophil granules (Luna stain).
doi:10.1371/journal.ppat.1000441.g001
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PLoS Pathogens | www.plospathogens.org 3 May 2009 | Volume 5 | Issue 5 | e1000441Figure 2. Identification of salivary proteins from Lu. longipalpis that produce a cellular immune response in dogs. (A) A schematic
representation of the reverse antigen screening approach based on the intradermal injection of DNA plasmids in dogs previously exposed to sand fly
bites (first exposure, E1; second exposure, E2; third exposure, E3). (B–F) Dogs pre-exposed to sand fly bites were challenged intradermally with DNA
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PLoS Pathogens | www.plospathogens.org 4 May 2009 | Volume 5 | Issue 5 | e1000441Figure 3. Sand fly salivary recombinant proteins produce a DTH response in dogs previously exposed to sand flies. (A) Purity of the
recombinant salivary proteins produced by HEK-293F mammalian cells and purified by a HPLC nickel trap column. (B) The diameter of erythema in
the absence (e) or presence (¤) of induration for each dog at the site of injection 48 h after challenge with salivary gland homogenate (SGH), PBS,
recombinant proteins rLJL143 and rLJM17 (reactive), rLJM111 (non-reactive) and a non-related tick recombinant protein TB179. (C) Representative
H&E staining and immunohistochemical labeling of T cells (anti-CD3) and macrophages (Mac387) at the injection sites of rLJL143, rLJM17 and
rLJM111. Note marked dermal infiltrates of inflammatory cells characterized as CD3
+ T cells and scattered macrophages (Mac387) with rLJL143 and
rLJM17; rLJM111 is negative.
doi:10.1371/journal.ppat.1000441.g003
plasmids and one pair of salivary gland homogenate (SGH) and PBS (positive and negative controls, respectively) and investigated 48 h post-
injection. (B) The number of dogs showing local induration and/or erythema at the site of injection for 35 DNA plasmids coding for secreted salivary
molecules. Yellow bars highlight the response of dogs to LJM17 and LJL143. (C) Photograph to demonstrate specificity of the cellular reaction to DNA
plasmids and SGH. (D) The diameter of erythema in the absence (e) or presence (¤) of induration for each dog at the site of injection of SGH, PBS,
LJL143 and LJM17 (reactive plasmids) and LJL04 and LJM111 (intermediate and non-reactive plasmids, respectively). (E–F) Skin biopsies (6mm)
obtained from injection sites were cut in half and processed for histology and RNA extraction. (E) Representative H&E staining and
immunohistochemical labeling of dermal T cells (anti-CD3) and macrophages (Mac387) at the injection sites of SGH, LJL143, LJM17 and LJM111.
Note marked dermal infiltrates of inflammatory cells characterized as CD3+ T cells and scattered macrophages (Mac387) in the SGH, LJL143 and
LJM17. There is no inflammation with LJM111. (F) Reverse-transcriptase quantitative PCR showing the expression levels of IFN-c, IL-12, IL-4 and TGF-b
for LJL143, LJM17, a pair of SGH and control (a mix of PBS and empty plasmid) 48 h post-injection. Error bars represent means6S.E.
doi:10.1371/journal.ppat.1000441.g002
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PLoS Pathogens | www.plospathogens.org 5 May 2009 | Volume 5 | Issue 5 | e1000441Figure 4. Dogs immunized with the Lu. longipalpis salivary molecules LJM17 or LJL143 develop strong and specific humoral and
cellular immune responses. (A) Total IgG and (B) IgG1 and IgG2 antibody levels up to day 224 in dogs immunized with either LJM17 (n=5), LJL143
(n=5) or the empty plasmid (n=5). LJL143- and LJM17-immunized dogs were tested using the appropriate recombinant proteins (LJL143 and
LJM17). Dogs immunized with the empty vector (control dogs) were tested against both recombinant proteins for IgG, (LJL143-control, LJM17-
control), IgG1 (IgG1-control) and IgG2 (IgG2-control). (C) In vitro IFN-c production by PBMC from LJL143- and LJM17-immunized and control dogs
stimulated with media (Med), ConcavalinA (ConA), salivary gland homogenate (SGH), rLJM17 or rLJL143 two weeks after the final vaccination. Error
bars represent means6S.E.
doi:10.1371/journal.ppat.1000441.g004
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PLoS Pathogens | www.plospathogens.org 6 May 2009 | Volume 5 | Issue 5 | e1000441by a viral vector boost (Figure 4A,B). Furthermore, IgG2 was the
predominant IgG subclass in immunized dogs (Figure 4B).
Following the viral vector boost, PBMC from control or
LJL143- and LJM17-immunized dogs were isolated and stimulat-
ed with recombinant proteins or SGH. PBMC from LJL143-
immunized dogs produced over 3600 pg/ml and 1200 pg/ml of
IFN-c following stimulation with rLJL143 and SGH, respectively
(Figure 4C). In LJM17-immunized dogs, IFN-c production was
also high at 1813 pg/ml and 446 pg/ml after stimulation with
rLJM17 and SGH, respectively (Figure 4C), Moreover, IFN-c
production was specific to the recombinant proteins since
stimulation of PBMC from LJL143-immunized dogs with rLJM17
produced background levels of IFN-c and vice versa (Figure 4C).
Bites of Lutzomyia longipalpis sand flies induce a strong
focal and systemic adaptive immune response in dogs
immunized with LJL143 or LJM17
LJL143- and LJM17-immunized dogs produced a strong Th1
systemic humoral and cellular response to the corresponding
salivary proteins (Figure 4). To determine whether this immunity is
maintained under natural conditions, these dogs were exposed to
sand fly bites, the natural route of transmission. A distinct focal
cellular infiltration of CD3
+ cells and a few scattered macrophages
was observed 48 h following the bites from 20 or five uninfected
flies in dogs immunized with LJM17 or LJL143 (Figure 5A, Figure
S1). RNA from biopsies taken at the bite site was used to
determine the expression of key cytokines 48 h after sand fly bites.
Following bites by 20 uninfected flies, LJM17-immunized dogs
showed a polarized Th1 immune response characterized by a
significant induction of IFN-c and IL-12 (P,0.03) with low levels
of IL-4 and the regulatory cytokine TGF-b (Figure 5B). This
expression profile was also observed in response to 5 uninfected
sand fly bites. Interestingly, LJL143-immunized dogs induced a
different profile when challenged with 20 compared to 5 sand flies.
TGF-b was the dominant cytokine induced following 20 bites
(P,0.03) with low expression levels for IFN-c, IL-12 and IL-4
(Figure 5B). In contrast, LJL143-immunized dogs challenged with
5 sand flies produced five times the expression levels of IFN-c
compared to those observed in controls and low levels of IL-4
expression (Figure 5B). To assess whether altered feeding behavior
of infected sand flies (caused by parasite blockage of the stomodeal
valve) influences the nature of the recall response, LJL143- and
LJM17-immunized dogs were simultaneously exposed to the bites
of 10 sand flies infected with L. i. chagasi. Forty-eight h following
challenge with infected sand flies, both groups of dogs produced a
strong focal cellular infiltration (Figure S2) and a cytokine profile
similar to that of uninfected sand flies (Figure 5C). Analysis of
PBMC one week after sand fly challenge showed that the
frequency of CD3
+ cells producing IFN-c following stimulation
with the appropriate recombinant proteins was considerably larger
in LJL143- and LJM17-immunized dogs and showed a signifi-
cantly higher mean fluorescence intensity (MFI) (P,0.05)
compared to cells from control dogs (Figure 5D). Further analysis
showed that CD3
+ CD4
+ T cells were the source of IFN-c in
immunized dogs (Figure 5E).
Macrophages efficiently kill Leishmania infantum chagasi
in vitro following the addition of SGH-stimulated LJL143-
and LJM17-specific lymphocytes
Immunization of dogs with the salivary proteins LJL143 and
LJM17 resulted in a strong focal and systemic CMI against sand
fly bites, the natural route of Leishmania transmission. To test
whether this immunity has an adverse effect on Leishmania
parasites, macrophages from PBMC of LJL143- and LJM17-
immunized or control dogs were infected with L. i. chagasi in vitro.
The addition of SGH-stimulated autologous lymphocytes from
LJL143- and LJM17-immunized dogs resulted in a 74% and 82%
(P,0.0001) reduction of infection in macrophages, respectively
(Figure 6). In contrast, the percent of infected macrophages was
not altered by the addition of SGH-stimulated autologous
lymphocytes from PBMC of control dogs.
Discussion
We propose the inclusion of salivary antigens of the sand fly Lu.
longipalpis, the only established vector of L. i. chagasi in Latin
America, as a component of anti-Leishmania vaccines against CVL.
This is based on the 1) induction of a strong Th1 cellular immune
response, the hallmark of protection against leishmaniasis, in dogs
immunized with two novel salivary proteins from the vector Lu.
longipalpis; 2) efficient recall of this Th1 immunity in the skin at the
bite site of infected sand flies, important when considering that
Leishmania are co-deposited with salivary proteins during probing
and feeding; 3) evidence that immunity to these salivary proteins
has an adverse effect on L. i. chagasi.
From a repertoire of 35 salivary molecules from Lu. longipalpis,
RAS correctly identified two salivary proteins, LJL143 and
LJM17, as inducers of CMI in dogs. It is important to note that
the antigens identified in this study differ from those eliciting
immune responses in rodent models [15,16,17]. LJM19, a salivary
molecule from Lu. longipalpis, conferred protection from visceral
leishmaniasis through induction of a strong DTH response in
hamsters [16] but induced a weak response in dogs (Figure 2). This
may be due to the restriction imposed by the repertoire of the
major histocompatibility complex class II molecules present in
different animals. Therefore, one can expect that immunogenic
antigens will vary in different animals. This demonstrates the
power of RAS in large laboratory animals such as dogs for the
rapid screening of antigens inducing CMI. For this reason, the
RAS technique represents a significant improvement in the
selection of appropriate vaccine candidates whereby it permits
screening of populations targeted by a vaccine, including dogs and
humans, for antigens inducing a cellular response.
In dogs pre-exposed to sand fly bites, LJL143 and LJM17
induced a distinct cellular infiltration characterized by CD3
+
lymphocytes, macrophages and notably, the absence of eosino-
phils. This differs from the response to natural bites that produced
a mixed response including a substantial number of eosinophils
and suggests that LJL143 and LJM17 are not likely to induce an
allergic response typically associated with exposure to insect saliva.
This was further supported by the lack of an allergic response in
immunized dogs following challenge by up to 35 sand fly bites, an
important consideration in the selection of salivary vaccine
candidates.
Dogs immunized with LJL143 or LJM17 showed a consistent
systemic adaptive immune response indicative of a Th1 profile.
This was demonstrated by the dominance of IgG2 antibodies
throughout the study period and the substantial production of
IFN-c by CD3
+CD4
+ T cells stimulated with SGH or recombi-
nant proteins. Considering that beagles are out bred, this
consistency is encouraging and bodes well for the use of these
antigens in the field.
A Leishmania vaccine has a better chance of success under field
conditions if it generates a rapid immune response in the skin
following the deposition of a relatively low dose of parasites [20] by
an infective sand fly. This immune response should be specific to
an antigen delivered during the bite, be it Leishmania antigens or
Immunity to Sand Fly Salivary Proteins in Dogs
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bites, uninfected and infected, elicited a distinct and comparable
cellular recruitment mediated by lymphocytes at the bite site in
dogs immunized with either LJL143 or LJM17. The cytokine
profile, assessed 48 h post bites, was characterized by the presence
of IFN-c and IL-12 and the absence of IL-4 in LJM17-immunized
dogs challenged with 5, 10 or 20 sand fly bites. This profile was
similar in LJL143-immunized dogs challenged with 5 sand flies.
However, the response in these dogs to 10 and 20 bites was low
with the exception of TGFb. The presence of high levels of TGFb,
a regulatory cytokine, suggests that this may be a regulatory
mechanism to dampen an earlier burst of IFN-c production. Thus,
the differences observed in cytokine levels may be explained by
different kinetics of the immune response to the two molecules
combined with the different number of bites received. Indeed,
PBMC of LJL143-immunized dogs produced high levels of IFN-c
following stimulation with SGH.
We hypothesized that anti-saliva immunity if generated against
a Th1 polarizing antigen can potentially have an adverse effect on
the parasites deposited together with saliva. In vitro, macrophages
infected with L. i. chagasi efficiently killed the parasites following the
addition of autologous T cells from LJL143- and LJM17-
immunized dogs stimulated by SGH showing a 74% and 82%
reduction of infection in macrophages respectively. This
Figure 5. Bites of Lu. longipalpis sand flies induce a strong focal and systemic adaptive cellular immune response in dogs immunized
with LJL143 or LJM17. (A–C) Dogs were exposed to uninfected and infected sand flies for 10 min one month after the final immunization with
either LJM17, LJL143 or the empty plasmid (control). (A–C) Skin biopsies (6mm) obtained from bite sites 48 h post challenge with 20 and five
uninfected and 10 infected sand flies were cut in half and processed for histology and RNA extraction. (A) Representative H&E staining and
immunohistochemical labeling of T cells (anti-CD3) and macrophages (Mac387) at the bite sites of 20 uninfected sand flies in LJL143- and LJM17-
immunized and control dogs. (B) Reverse-transcriptase quantitative PCR showing the expression levels of IFN-c, IL-12, IL-4 and TGF-b at the bite sites
of 20 or five uninfected sand flies in LJL143- and LJM17-immunized and control dogs (for control dogs RNA was combined from sites of 20 and 5
uninfected sand fly bites). (C) Same as (B) using 10 infected sand flies. Histological sections from bite sites of five uninfected and 10 infected sand flies
are provided as Figure S1 and Figure S2, respectively. (D–E) PBMC from LJL143- and LJM17-immunized and control dogs obtained one week after
exposure to sand flies. (D) Frequency and mean fluorescence intensity (MFI) of CD3
+ T cells following stimulation with medium, rLJL143 or rLJM17. (E)
Frequency of CD4
+ and CD8
+ T cells expressing IFN-c in PBMC from LJL143- and LJM17-immunized dogs. Error bars represent means6S.E. * P,0.05,
** P,0.01.
doi:10.1371/journal.ppat.1000441.g005
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parasites. How this anti-saliva immunity plays out in vivo remains
to be fully elucidated. It could act through an initial indirect killing
of Leishmania in situ, acceleration of specific anti-Leishmania
immunity or a combination of both [14,15,16,17]. Acceleration
of anti-Leishmania immunity can occur as a result of a more rapid
processing of killed parasites or through the effect of an altered
cytokine milieu on the nature and commitment of cells recruited to
the site by anti-saliva immunity.
In conclusion, induction of immune correlates of protection in
dogs immunized with salivary proteins from Lu. longipalpis is a
strong predictor that these molecules will be an advantageous
addition to an anti-Leishmania canine vaccine. Sand fly salivary
molecules have been neglected as a component of anti-Leishmania
vaccines despite their reported immunogenicity in rodent models
and humans [16,17,21,22], and their unique advantage as a
permanent feature of natural transmission. Salivary proteins can
provide a novel source of antigens that may complement or
synergize promising Leishmania-based vaccines providing an
independent arm of the immune response that could be of value
in the control of leishmaniasis.
Materials and Methods
Animals
One to two year old female beagles (Marshall Farms) were
housed at the NIH animal facility following the Animal Care and
User Committee guidelines. Four to seven day old Lutzomyia
longipalpis female sand flies (Jacobina colony) were used in
experiments. Salivary glands were sonicated, centrifuged at
10,000 g for 3 min and used immediately. L. i. chagasi (BA262
strain) promastigotes were cultured as previously described [16].
DNA plasmids
DNA plasmids were constructed and purified as previously
described [16], filter sterilized and stored at 270uC.
Recombinant proteins
Specific Lu. longipalpis salivary cDNA containing a histidine tag
at the 39 end were cloned into the VR2001-TOPO expression
vector [23]. HEK-293F cells were transfected and supernatants
collected at 72 h. Expressed proteins were purified by HPLC
(DIONEX) using a HITRAP Chelating HP column (GE
HealthCare) charged with Ni2SO4 0.1M. Proteins were eluted
using an imidazole gradient, dialyzed against PBS and stored at
270uC.
Recombinant canarypoxvirus
Canarypoxviruses from ALVAC vectors expressing the LJL143
(vCP2389) or LJM17 (vCP2390) were generated as previously
described [24]. PUREVAX ferret distemper vaccine (Merial) was
used as control.
Sand fly infection
Sand flies were fed through a chick skin membrane on a
suspension of 3610
6 L. i. chagasi procyclic promastigotes/ml of
heparinized blood containing penicillin and streptomycin. Flies
with mature infections were used for transmission.
Exposure of dogs to sand fly bites
Dogs were sensitized three times weekly with 20 sand flies
placed in custom made chambers and secured to the shaved side of
the neck with a Velcro collar for 10 min. For assessing the skin
immune response, five and 20 uninfected and 10 infected sand flies
were placed in small vials and hand-held to marked sites on the
shaved belly of dogs for 10 min. Dogs were handled without any
chemical restraint.
DTH measurement
The diameter of erythema and the induration (elevation over
1 mm) on the skin of dogs were measured 48 h post-injection.
Skin biopsies
6mm skin punch biopsies (Acuderm) were cut in two. One half
was fixed in neutral-buffered formaldehyde (10% formalin) for
histology and the other was stored in RNALATER (Sigma-
Aldrich) for RNA extraction.
Histology and Immunohistochemistry
Formalin fixed skin biopsies were embedded in paraffin. Four
mm sections were processed for staining with hematoxylin and
eosin (H & E) and Luna’s stain. Additional sections were labeled
with anti-CD3 and Mac387. Sections were incubated with
primary rabbit anti-human CD3 (Dako, Glostrup, Denmark)
and mouse anti-human Mac387 (Serotec, Raleigh, NC) at 1:300
and 1:400 respectively for 1 h. For CD3, a secondary biotinylated
goat anti-rabbit antibody was used at 1:500 for 15 min (Vector
Figure 6. Macrophages efficiently kill L. i. chagasi in vitro following the addition of autologous lymphocytes from LJL143- and
LJM17-immunized dogs stimulated with SGH. Percent of infected macrophages 72 h after the addition of autologous lymphocytes alone
(Med), or together with ConA or SGH from PBMC of LJL143- and LJM17-immunized and control dogs. The percentage of amastigote-infected
macrophages was evaluated by microscopic examination of Giemsa-stained preparations. Error bars represent means6S.E. * P,0.0001.
doi:10.1371/journal.ppat.1000441.g006
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TASTIN Elite ABC reagent (Vector) and DAB chromagen. For
Mac387, a secondary antibody labeled with Mach 4 HRP Polymer
(Biocare Medical, Concord, CA) was used following the manu-
facturer’s recommendation and detected by DAB chromagen.
Reverse antigen-screening (RAS)
Dogs pre-exposed to sand fly bites were anesthetized and
randomly injected intradermally with 40 mL of 35 salivary DNA
plasmids (20 ug each) or recombinant proteins (300 ng) diluted in
PBS and separated from each other by ,15mm. Controls
included PBS, a pair of Lu. longipalpis SGH (1 mg), 20 mgo f
control vector or 300 ng of rTB179, a tick recombinant salivary
protein.
Immunization of dogs
At day 0, five dogs per group were immunized intradermally
(ID) in the ear pinna with 500 mg of LJL143 DNA plasmid (group
one), LJM17 DNA plasmid (group two) and VR2001 control
vector (group three). The dogs were given a second and third
immunization at days 14 and 28 with 500 mg of the appropriate
DNA plasmids injected in both thighs intramuscularly (IM)
coupled to electroporation (Sphergen). At day 42, the dogs were
immunized ID with 100 mg of rLJL143 for group 1, rLJM17 for
group 2 or BSA for group 3 together with 300 mg CpG ODN in
20% EMULSIGEN (MVP laboratories). At day 210, the dogs
received a vaccine booster (IM) in the left quadriceps using 10
8 pfu
of recombinant canarypoxvirus expressing LJL143 or LJM17 for
group two, and PUREVAX control canarypoxvirus for group
three.
Direct enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (MAXSORP, Nunc) were coated with 100 ml
of 2 mg/ml rLJM17 or rLJL143 or Lu. longipalpis SGH (five salivary
gland pairs/ml) overnight at 4uC. Plates were blocked with 4%
fetal bovine serum (FBS) in PBS-TWEEN 0.05% at RT for 2 h.
A100 ml of dog sera (1:50) was incubated for 1 h at 37uC. After
three washes with PBS-T, sheep anti-dog IgG (1:5000), goat anti-
dog IgG1 (1:500) or sheep anti-dog IgG2 (1:500) phosphatase
alkaline-conjugated antibodies (Bethyl Laboratories Inc.) were
incubated for 1 h at 37uC. Plates were developed with p-
nitrophenylphosphate (Sigma-Aldrich) and absorbance was read
at 405nm using a SPECTRAMAX Plus (Molecular Devices).
Capture ELISA
PBMC were isolated as previously described [25]. A million
cells per well of a 96 well-plate (Research & Diagnostic systems)
were cultured for 72 h in 500 ml of RPMI supplemented with 20%
heat-inactivated FBS, 2mM L-glutamine, 100 units/ml penicillin
and 100 ml/ml streptomycin (cRPMI) with either two pairs of
SGH, ConA (4 mg), rLJM17 (4 mg) or rLJL143 (4 mg). IFN-c
production was measured from supernatants using QUANTI-
KINE ELISA (Research & Diagnostic Systems). Absorbance
(405 nm) was measured using SPECTRAMAX Plus (Molecular
Devices).
Real-time PCR
Isolation of RNA from skin and first strand cDNA synthesis was
performed as previously described [16]. DNA was amplified with
specific dog primers (Operon Biotechnologies, Inc.) and probes
(Roche Diagnostics) for IFN-c, IL-12, IL-4 and TGF-b as
previously described [16]. The expression level of genes of interest
was normalized to GAPDH levels.
Flow cytometry
Two million PBMC were cultured in a ml of cRPMI for 18 h in
the presence of either ConA (4 mg), rLJM17 (20 mg) or rLJL143
(20 mg) at 37uCi n5 %C O 2. Cells were incubated with 2 mM final
concentration of GolgiStop (BD Pharmingen) for 4 h, washed with
PBS-5% FBS, and blocked with PBS-10% FBS for 30 min at 4uC.
Cells were stained with FITC-labeled anti-CD3 (CA17.2A12, BD
Pharmingen) and ALEXA FLUOR 647-labeled anti-CD8
(YCATE55.9, BD Pharmingen) for 30 min at 4uC, washed twice,
fixed and permeabilized with CYTOFIX/CYTOPERM Plus (BD
Pharmingen) and stained with PE-labeled anti-IFN-c (CC302, BD
Pharmingen). A minimum of 200,000 cells were acquired using a
FACSCalibur flow cytometer (BD Biosciences) and analyzed with
CELLQUEST Pro software.
In vitro Leishmania killing assay
Canine monocyte-derived macrophages were prepared as
previously described [26]. PBMC collected from immunized dogs
were plated in 8 well chamber slides (BD FALCON) at 5610
6 cells
per ml and incubated for 30 min at 37uC with 5% CO2. Non-
adherent cells (autologous T cells) were removed and cultured
separately. After 5 d of culture, macrophages were infected with
stationary phase L. i. chagasi at a 5:1 parasites to macrophage ratio
for 2 h at 37uC- 5% CO2. Non-internalized parasites were
removed by gentle washing. Infected macrophages were cultured
for 72 h in the presence of autologous lymphocytes at a 2:1
lymphocyte to macrophage ratio and stimulated with Lu. longipalpis
SGH (2 pairs) or ConA (4 mg). The percentage of infected
macrophages was assessed by microscopic examination of Giemsa-
stained preparations.
Statistical analysis
Statistical significance was tested with the two-tailed student’s t-
test using Graph Pad 4.0 Prism Software.
Supporting Information
Figure S1 Bites of Lu. longipalpis sand flies induce a strong focal
cellular immune response in dogs immunized with LJL143 or
LJM17. Dogs were exposed to 5 uninfected sand flies for 10 min
one month after the final immunization with either LJM17,
LJL143 or empty plasmid (control). Skin biopsies (6mm) obtained
from bite sites 48 h post challenge were processed for histology.
Representative H&E staining and immunohistochemical labeling
of T cells (anti-CD3) and macrophages (Mac387) at the bite sites in
LJL143- and LJM17-immunized and control dogs.
Found at: doi:10.1371/journal.ppat.1000441.s001 (10.09 MB
TIF)
Figure S2 Bites of L. i. chagasi infected sand flies induce a strong
focal cellular immune response in dogs immunized with LJL143 or
LJM17. Dogs were exposed to ten L. i. chagasi infected sand flies for
10 min one month after the final immunization with either
LJM17, LJL143 or empty plasmid (control). Skin biopsies (6mm)
obtained from bite sites 48 h post challenge were processed for
histology. Representative H&E staining and immunohistochemical
labeling of T cells (anti-CD3) and macrophages (Mac387) at the
bite sites in LJL143- and LJM17-immunized and control dogs.
Found at: doi:10.1371/journal.ppat.1000441.s002 (7.93 MB TIF)
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